跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
連結會在新分頁中打開
English
中文
在 臺北醫學大學 搜尋內容
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
查看斯高帕斯 (Scopus) 概要
張 偉斌
教授
,
醫務管理學系
合聘教授
,
國際生技醫療管理博士學位學程
成員
,
臺北醫學大學人工智慧醫療研究中心
https://orcid.org/0000-0003-2107-612X
電子郵件
wpchang
tmu.edu
tw
h-index
1498
引文
23
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2011
2026
每年研究成果
概覽
指紋
網路
專案
(19)
研究成果
(69)
資料集
(2)
類似的個人檔案
(6)
指紋
查看啟用 Wei Pin Chang 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Cohort Analysis
100%
Hazard Ratio
68%
Osteoporosis
51%
Diseases
38%
Kawasaki Disease
38%
Atopic Dermatitis
31%
Kidney Stone
25%
Cholesteatoma
25%
Endometriosis
25%
Apoplexy
25%
Disseminated Herpes Zoster
25%
Breast Cancer
25%
Obstructive Sleep Apnea
25%
Ankylosing Spondylitis
25%
Malignant Neoplasm
25%
Proportional Hazards Model
24%
Allergic Rhinitis
21%
Survival Rate
20%
Odds Ratio
18%
Asthma
16%
Retrospective Cohort Study
15%
Cardiovascular Disease
15%
Genetics
15%
Prevalence
14%
Irritable Bowel Syndrome
14%
Preschooler
14%
Congestive Heart Failure
14%
Genome Wide Association Study
13%
Immunoglobulin E
13%
Chronic Obstructive Pulmonary Disease
12%
Functional Gastrointestinal Disorder
12%
Peritoneum Cancer
12%
Krukenberg Tumor
12%
Intraperitoneal Chemotherapy
12%
Scoliosis
12%
Nephrectomy
12%
Transitional Cell Carcinoma
12%
Gene Overexpression
12%
Clear Cell Renal Cell Carcinoma
12%
Chronic Rhinosinusitis
12%
Hernioplasty
12%
Inguinal Hernia
12%
Major Depressive Episode
12%
Big Data
12%
Genetic Risk
12%
Drug Repositioning
12%
Parkinson's Disease
12%
Acneiform Eruption
12%
Chemotherapy
12%
Cancer Risk Factor
12%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
64%
Sleep Disordered Breathing
38%
Mucocutaneous Lymph Node Syndrome
38%
Atopic Dermatitis
29%
Asthma
26%
Nephrolithiasis
25%
Kidney Stone
25%
Cerebrovascular Accident
25%
Diseases
16%
Ankylosing Spondylitis
16%
Drug Repositioning
14%
Prevalence
14%
Immunoglobulin E
13%
Digestive System Function Disorder
12%
Chronic Obstructive Lung Disease
12%
Scoliosis
12%
Abdominal Wall Hernia
12%
Dimethylnitrosamine-Induced Liver Fibrosis
12%
Paclitaxel
12%
Hernia
12%
Disease Activity
12%
Rheumatoid Arthritis
12%
Phospholipase D
12%
Erectile Dysfunction
12%
Prostate Hypertrophy
12%
Parkinson's Disease
12%
Gallstone
12%
Pembrolizumab
12%
Non Small Cell Lung Cancer
12%
Chemotherapy Regimens
12%
Alkaline Phosphatase
12%
Liver Cell Carcinoma
12%
Rat
12%
Atezolizumab
12%
RGS Protein
12%
Inflammatory Arthritis
12%
Autism
12%
Cardiovascular Disease
12%
Bevacizumab
12%
Attention Deficit Disorder
12%
Survival Rate
12%
N-Nitrosodimethylamine
9%
Antipsychotic
9%
Combination Therapy
9%
Neoplasm
6%
Peritoneum Cancer
6%
Ovary Carcinoma
6%
Liver Fibrosis
6%
Aspartate Aminotransferase
6%
Alanine Aminotransferase
6%
Nursing and Health Professions
Cohort Analysis
35%
Hazard Ratio
25%
Cholesteatoma
25%
Mucocutaneous Lymph Node Syndrome
25%
Cerebrovascular Accident
25%
Confidence Interval
20%
Prevalence
16%
Cost Effectiveness Analysis
16%
National Health Insurance
14%
Digestive System Function Disorder
12%
Prostate Hypertrophy
12%
Information Systems
12%
Scoliosis
12%
Atezolizumab
12%
Pembrolizumab
12%
Endometriosis
12%
Bevacizumab
12%
Non Small Cell Lung Cancer
12%
Chemotherapy
12%
Obstructive Lung Disease
12%
Postoperative Nausea and Vomiting
12%
Liver Cell Carcinoma
12%
Asthma
12%
Sleep Disordered Breathing
12%
Job Stress
12%
Chronic Rhinosinusitis
12%
Autism
12%
Electronic Health Record
12%
Perception Deafness
12%
Nurse
12%
Irritable Colon
12%
Malignant Neoplasm
12%
Quality Adjusted Life Year
12%
Survival Rate
11%
Diseases
10%
Immunoglobulin E
10%
Economic and Social Development
9%
Combination Therapy
9%
Progression Free Survival
7%
Proportional Hazards Model
7%
Recurrent Disease
6%
Logistic Regression Analysis
5%
Allergic Rhinitis
5%
Patient with Kawasaki Disease
5%
